Home » Topics » Regulatory » EMA

EMA
RSS

Sepracor withdraws marketing authorization application for Lunivia (eszopiclone)

May 19, 2009

The European Commission withdraws marketing authorization for Velosulin

April 20, 2009

CHMP recommends marketing authorization for Astellas' Modigraf in transplant rejection

March 24, 2009

CHMP recommends marketing authorization for HRA's emergency contraceptive ellaOne

March 24, 2009

Bristol-Myers Squibb withdraws marketing authorization application for Ixempra

March 23, 2009

EMEA recommends continued vaccination with Gardasil

Feb. 23, 2009

FDA issues public health advisory for Raptiva, EMEA recommends suspension

Feb. 23, 2009

CHMP recommends granting marketing authorization to Nycomed's Pantozol Control

Feb. 20, 2009

Merck Sharp & Dohme withdraws MAA to EMEA for vorinostat MSD in CTCL

Feb. 19, 2009

CHMP recommends new indication for Nycomed's TachoSil

Dec. 29, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for April 21, 2025.
Makary’s vision for slimmed-down US FDA somewhat reassuring
BioWorld
Nearly three weeks into the job, U.S. FDA Commissioner Marty Makary provided a comprehensive overview of his vision for the much-reduced agency, even as he’s...
Dupixent bounces back in treating hives with FDA approval
BioWorld
The U.S. FDA issued a complete response letter in October 2023 for Dupixent (dupilumab) in treating chronic hives but has now approved the monoclonal antibody for...
Ouch! Tariffs hit med tech harder than expected
BioWorld MedTech
First quarter earnings reports from Johnson & Johnson and Abbott Laboratories provided some surprising insights into the likely hit med-tech companies will...